Meta-analysis: Vitamin D and non-alcoholic fatty liver disease

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 3, 2013, Pages 246-254

  Eliades, M ^a   Spyrou, E ^a   Agrawal, N ^a   Lazo, M ^b,c   Brancati, F L ^b,c,d   Potter, J J ^b   Koteish, A A ^b   Clark, J M ^b,c,d   Guallar, E ^c,d   Hernaez, R ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; LIVER ENZYME;

ARTICLE; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; HEPATOGRAPHY; HUMAN; LIVER BIOPSY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FATTY LIVER; HUMANS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84879735651     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12377     Document Type: Article

References (58)

1. Lazo M, Clark JM,. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: 339-50.
2. Bugianesi E, Leone N, Vanni E, et al,. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
3. Tilg H, Moschen AR,. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836-46.
4. Holick MF,. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
5. DeLuca HF,. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80 (6 Suppl.): 1689S-96S.
6. Verstuyf A, Carmeliet G, Bouillon R, Mathieu C,. Vitamin D: a pleiotropic hormone. Kidney Int 2010; 78: 140-5.
7. Angelico F, Del Ben M, Conti R, et al,. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 90: 1578-82.
8. Chiu KC, Chu A, Go VL, Saad MF,. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79: 820-5.
9. Pittas AG, Chung M, Trikalinos T, et al,. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med 2010; 152: 307-14.
10. Ganji V, Zhang X, Tangpricha V,. Serum 25-hydroxyvitamin D concentrations and prevalence estimates of hypovitaminosis D in the U.S. population based on assay-adjusted data. J Nutr 2012; 142: 498-507.
11. George N, Kumar TP, Antony S, Jayanarayanan S, Paulose CS,. Effect of vitamin D3 in reducing metabolic and oxidative stress in the liver of streptozotocin-induced diabetic rats. Br J Nutr 2012; 108: 1410-8.
12. Roth CL, Elfers CT, Figlewicz DP, et al,. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology 2012; 55: 1103-11.
13. Zhang A, Wang Y, Xie H, Zheng S,. Calcitriol inhibits hepatocyte apoptosis in rat allograft by regulating apoptosis-associated genes. Int Immunopharmacol 2007; 7: 1122-8.
14. Potter JJ, Liu X, Koteish A, Mezey E,. 1,25-dihydroxyvitamin D3 and its nuclear receptor repress human alpha1 (I) collagen expression and type I collagen formation. Liver Int 2013; 33: 677-86.
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP,. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-9.
16. Stroup DF, Berlin JA, Morton SC, et al,. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
17. Cooper HM, Hedges LV,. The Handbook of Research Synthesis. New York: Russell Sage Foundation, 1994.
18. Foster T, Chalasani NP, Liangpunsakul S, et al,. The association of serum vitamin D concentrations and non alcoholic fatty liver disease (NAFLD): the multiethnic study of atherosclerosis. Hepatology 2011; 54 (S1): 1129A-30A.
19. Dasarathy J, Periyalwar P, Allampati S, et al,. Hypovitaminosis D associated with more advanced non alcoholic fatty liver disease. Hepatology 2012; 56 (S1): 889A-90A.
20. Li L, Zhang L, Pan S, Wu X, Yin X,. No significant association between vitamin D and nonalcoholic fatty liver disease in a Chinese population. Dig Dis Sci 2013; doi: 10.1007/s10620-013-2658-1 [Epub ahead of print].
21. Seo JA, Cho H, Kim YJ, et al,. Vitamin D status and nonalcoholic fatty liver disease in Koreans: Korean Genome Epidemiologic Study (KoGES). Endocr Rev 2011; 32: P2-121.
22. Rhee EJ, Kim MK, Park SE, et al,. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocr J 2013; doi: 10.1507/endocrij.EJ12-0387 [Epub ahead of print].
23. Kim D, Chung GE, Lim SH, et al,. Serum vitamin D is inversely associated with nonalcoholic fatty liver disease in general population. J Hepatol 2012; 56 (Suppl. 2): S511.
24. Fan L, Tu X, Zhu Y, et al,. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol 2005; 20: 249-55.
25. Abawi M, Birerdinc A, Baranova A, et al,. Vitamin D levels in non-alcoholic fatty liver disease (NAFLD) patients correlate with apoptosis and serum levels of M30. Am J Gastroenterol 2011; 106 (Suppl. 2): S121.
26. Barchetta I, Angelico F, Del Ben M, et al,. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011; 9: 85.
27. Catena C, Cosma C, Camozzi V, et al,. Non-Alcoholic Fatty Liver Disease is Not Associated with Vitamin D Deficiency in Essential Hypertension. High Blood Press Cardiovasc Prev 2013; doi: 10.1007/s40292-013-0010-7 [Epub ahead of print].
28. Jablonski KL, Jovanovich A, Holmen J, et al,. Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2013; http://dx.doi.org/10.1016/j.numecd.2012.12.006 [Epub ahead of print].
29. Katz K, Brar PC, Parekh N, Liu YH, Weitzman M,. Suspected nonalcoholic Fatty liver disease is not associated with vitamin d status in adolescents after adjustment for obesity. J Obes 2010; 2010: 1-7.
30. Kayaniyil S, Vieth R, Harris SB, et al,. Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J Clin Endocrinol Metab 2011; 96: 168-75.
31. Liangpunsakul S, Chalasani N,. Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci 2011; 56: 2124-9.
32. Manco M, Ciampalini P, Nobili V,. Low levels of 25-hydroxyvitamin D(3) in children with biopsy-proven nonalcoholic fatty liver disease. Hepatology 2010; 51: 2229; author reply 2230.
33. Nseir W, Taha H, Khateeb J, Grosovski M, Assy N,. Fatty liver is associated with recurrent bacterial infections independent of metabolic syndrome. Dig Dis Sci 2011; 56: 3328-34.
34. Nseir W, Assy N,. Association between 25-OH vitamin D concentrations and risk of coronary artery disease in patients with non alcoholic fatty liver disease. Hepatol Int 2011; 5: 183-4.
35. Targher G, Bertolini L, Scala L, et al,. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517-24.
36. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A,. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56: 952-64.
37. Cheung O, Sanyal AJ,. Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 351-9.
38. Albano E, Mottaran E, Occhino G, Reale E, Vidali M,. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 2005; 22 (Suppl. 2): 71-3.
39. Day CP,. From fat to inflammation. Gastroenterology 2006; 130: 207-10.
40. Arkan MC, Hevener AL, Greten FR, et al,. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 191-8.
41. Mitri J, Muraru MD, Pittas AG,. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr 2011; 65: 1005-15.
42. George PS, Pearson ER, Witham MD,. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med 2012; 29: e142-50.
43. Maestro B, Davila N, Carranza MC, Calle C,. Identification of a Vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003; 84: 223-30.
44. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG,. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003; 17: 509-11.
45. Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C,. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol 2005; 349: 248-60.
46. Maestro B, Campion J, Davila N, Calle C,. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 2000; 47: 383-91.
47. Gysemans CA, Cardozo AK, Callewaert H, et al,. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005; 146: 1956-64.
48. Riachy R, Vandewalle B, Kerr Conte J, et al,. 1,25-dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20. Endocrinology 2002; 143: 4809-19.
49. Nakano T, Cheng YF, Lai CY, et al,. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol 2011; 55: 415-25.
50. Gascon-Barre M, Demers C, Mirshahi A, Neron S, Zalzal S, Nanci A,. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 2003; 37: 1034-42.
51. Han S, Chiang JY,. Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes. Drug Metab Dispos 2009; 37: 469-78.
52. Han S, Li T, Ellis E, Strom S, Chiang JY,. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol Endocrinol 2010; 24: 1151-64.
53. Barchetta I, Carotti S, Labbadia G, et al,. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012; 56: 2180-7.
54. Abramovitch S, Dahan-Bachar L, Sharvit E, et al,. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011; 60: 1728-37.
55. Hernaez R, Lazo M, Bonekamp S, et al,. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-90.
56. Liangpunsakul S, Chalasani N,. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci 2005; 329: 111-6.
57. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al,. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012; 97: 1153-8.
58. Rosen CJ, Abrams SA, Aloia JF, et al,. IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab 2012; 97: 1146-52.